MindMed to Participate in June Investor Conferences
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in two upcoming investor conferences in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Jefferies Global Healthcare Conference
- Format: Presentation
- Date and Time: Thursday, June 5, 2025 at 12:50 PM ET
-
Location:
New York, NY - Webcast Link: Jefferies Global Healthcare Conference
-
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
- Format: Pre-recorded Fireside Chat
- Date and Time: Tuesday, June 17, 2025 at 7:00 AM ET
- Location: Virtual
- Webcast Link: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528715195/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.